Atrys Health Stock

Atrys Health Diluted EPS

The Diluted Earnings per Share of Atrys Health (ATRY.MC) as of Aug 15, 2026 is -1.32 EUR. In the previous year, Diluted Earnings per Share was -0.42 EUR — a change of 215.59% (lower).

Diluted EPS

-1.32EUR

YoY

215.59%

Last updated:

Diluted Earnings per Share of Atrys Health is 2026 -1.32 EUR. Diluted Earnings per Share of Atrys Health was 2025 -0.42 EUR. It decreases by 215.59% lower compared to the previous year.
Access this data via the Eulerpool API

Atrys Health Stock analysis

What does Atrys Health do? Atrys Health SA is a leading provider of medical services, founded in 2007 in Madrid, Spain, as a spin-off company of the Clinica Universidad de Navarra. The company's goal is to connect the limitless world of science and technology with the human component of healthcare. The business model of Atrys Health specializes in the development of products, services, and solutions in the field of medical imaging and cancer treatment. The company offers innovative technologies and medical services to help diagnose and treat patients better. Atrys Health consists of different business divisions focusing on the needs of clinical practice, research and development, and biotechnological production. The company aims to improve the efficiency and effectiveness of diagnosis, imaging, and treatment technologies to maximize results. The divisions of Atrys Health focus on various aspects of healthcare, including telemedicine, radiology, and proton therapy. Telemedicine provides a platform for remote treatments and medical consultation, improving access to specialists and enabling fast and effective diagnosis and treatment. The radiology division operates diagnostic centers specializing in medical imaging, equipped with the latest imaging technologies. The proton therapy division operates a proton therapy center in Madrid, offering advanced cancer treatment. Atrys Health offers a range of products tailored to the needs of clinical practice, research and development, and biotechnological production. Their key products include Atrilab, a leading platform for precision oncology diagnostics, Auriculum, a technology for precise radiation in cancer treatments, and Vida Oncology, a software solution for cancer treatment management. In conclusion, Atrys Health is a key player in medical imaging and cancer treatment, improving healthcare globally with advanced technologies and services. With their vision of combining innovative technologies with the human component of healthcare, Atrys Health will continue to lead in the healthcare industry. Atrys Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Atrys Health stock

Diluted Earnings per Share of Atrys Health is -1.32 EUR in 2026.

Diluted Earnings per Share of Atrys Health changed from -0.42 EUR to -1.32 EUR, representing a 215.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Atrys Health since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

Income Statement — Atrys Health

All Key Metrics — Atrys Health